Carl Zeiss Meditec


Carl Zeiss Meditec’s re-rating journey should continue further

21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."

Pages
61
Language
English
Published on
21/02/24
You may also be interested by these reports :
09/04/24
bioMerieux has reported better-than-expected Q1 organic sales growth, with healthy growth visible across both segments. Besides this, a promising ...

09/04/24
We have taken into account Bastide’s new contract win in the breathing assistance segment, which is expected to generate additional revenue of c.€10m ...

05/04/24
Slowdown in 2024E a nuisance but inconsequential for long-term equity story – TP cut to CHF 384.00 / Add reiterated

04/04/24
We have trimmed our estimates to factor in: 1. ACT quality woes that have persisted for longer than expected, and which will weigh on near-term ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO